Eupraxia Pharmaceuticals Inc. (T:EPRX*CA)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEDAR
Company Contact
Address: 2067 Cadboro Bay Road
#201, 1240-666 Burrard Street
VANCOUVER BC V6C 2X8
Tel: 1-416-4271235
Website: eupraxiapharma.com
IR: See website
<
Key People
Simon Pimstone
Non-Executive Independent Chairman of the Board
Bruce Cousins
President, Chief Financial Officer
James A. Helliwell
Chief Executive Officer, Director
Amanda Malone
Chief Scientific Officer
   
Business Overview
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its lead product candidate, EP-104IAR, is designed to meet the unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA). EP-104IAR contains a solid core of the active ingredient Fluticasone Propionate (FP) with an outer layer of the biocompatible polymer, PVA. In addition to EP-104IAR, the Company is also developing a pipeline of earlier-stage long-acting formulations. It develops pipeline candidates for a range of indications, such as post-surgical pain (EP-105), and post-surgical site infections (EP-201). The Company has completed a phase I, double-blind, placebo-controlled clinical study at three sites in Canada.
Financial Overview
For the three months ended 31 March 2022, Eupraxia Pharmaceuticals Inc revenues was not reported. Net loss decreased 58% to C$3.7M. Lower net loss reflects Stock-based compensation decrease of 81% to C$526K (expense), Loss on conversion of notes and special decrease from C$1.9M (expense) to C$0K, Fair Value Adjustments on Other Assets decrease from C$1.3M (expense) to C$0K.
Reporting Currency: Canadian Dollars
Enterprise value: N/A
Annual revenue (TTM): $0.00M as of Jun 30, 2022
EBITDA (TTM): -$16.42M as of Jun 30, 2022
Net annual income (TTM): -$17.82M as of Jun 30, 2022
Free cash flow (TTM): -$14.59M as of Jun 30, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 21,393,145 as of May 12, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.